Program Website

https://www.medicalcountermeasures.gov/

Uniform Guidance

Uniform Guidance Interim Final Rule - HHS

Findings Library

2023 Compliance Supplement

Part 3 - Compliance Requirements

Part 3 - Compliance Requirements (redline version)

2022 Compliance Supplement

Part 3 - Compliance Requirements

Part 3 - Compliance Requirements (redline version)

Federal Regulations

45 cfr 75 - uniform administrative requirements, cost principles, and audit requirements for hhs awards

Other

hhs.gov - grants policies & regulations

CFDA Historical Index

2020

Action/Change Type: publish
Change Description: Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development


2019

Action/Change Type: publish
Change Description: Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development


2018

Action/Change Type: publish
Change Description: Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development

Program Objective

The purpose of this program is to coordinate the acceleration of countermeasure and product advanced research and development by—(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect to such advanced research and development; (B) promoting countermeasure and product advanced research and development; (C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of the Public Health Service Act; and (D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development. The Public Health Service Act at 42 U.S.C. 247d-6a defines a qualified countermeasure as “…a drug (as that term is defined by section 321(g)(1) of title 21), biological product (as that term is defined by section 262(i) of this title), or device (as that term is defined by section 321(h) of title 21), that the Secretary determines to be a priority (consistent with sections 182(2) and 184(a) of title 6) to - (i) diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; or (ii) diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device that is used as described in this subparagraph”

Reported Expenditures

Expenditure Metrics

Contact Information

Rick A. Bright 330 Independence Ave SW, Room G-640, Washington, District of Columbia 20201, Washington, District of Columbia 20201 Email: Rick.Bright@hhs.gov Phone: 202-260-8535

Legal Disclaimer

This information is accumulated from various sources, including but not limited to, beta.sam.gov, cfda.gov, whitehouse.gov and the web sites from various government agencies. The accuracy and completeness of this information has not been verified. Accordingly, we do provide any warranties over the accuracy or completeness of this information. By using this site, you agree to accept all responsibility for inaccurate or incomplete information contained herein.